Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.

Grace M MooreSimon N PowellDaniel S HigginsonAtif J Khan

Published in: Breast cancer research and treatment (2022)

Our analyses suggest that 14% of ER+/Her2- patients may be HRD and therefore potentially eligible for treatments with HRD-directed therapies such as platinum agents and PARP inhibitors. As the ER+/Her2- subtype is the most common breast cancer subtype, this group of HRD patients is likely more sizable than that of HRD TNBC patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
dna damage
dna repair
risk factors
childhood cancer